日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients

HOBOE III期试验十年更新结果，比较曲普瑞林联合他莫昔芬或来曲唑，或唑来膦酸联合来曲唑治疗绝经前激素受体阳性早期乳腺癌患者

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.104085
Gravina, A; Gargiulo, P; De Laurentiis, M; Arenare, L; De Placido, S; Orditura, M; Cinieri, S; Riccardi, F; Ribecco, A S; Putzu, C; Del Mastro, L; Rossi, E; Ciardiello, F; Di Rella, F; Nuzzo, F; Pacilio, C; Caputo, R; Cianniello, D; Forestieri, V; Giuliano, M; Arpino, G; Orlando, L; Mocerino, C; Schettino, C; Piccirillo, M C; Gallo, C; Perrone, F
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

晚期子宫内膜癌同源重组修复状态：来自随机 II 期 MITOEND 3 试验的探索性生物标志物分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105919
Bartoletti, M; Passarelli, A; Fagotti, A; Andreetta, C; Tamberi, S; Lorusso, D; Pisano, C; Califano, D; Spina, A; De Angelis, C; Greco, F; De Cecio, R; Scaglione, G L; Russo, D; Ghizzoni, V; Cinieri, S; Sisoudiya, S D; Sokol, E S; Arenare, L; Schettino, C; Perrone, F; Farolfi, A; Pignata, S
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

外周单核细胞髓系衍生抑制细胞与接受卡铂+紫杉醇/avelumab治疗的单中心子宫内膜癌患者的分子亚型的关联（MITO-END3试验）

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04021-3
D'Alterio C, Rea G, Napolitano M, Coppola E, Spina A, Russo D, Azzaro R, Mignogna C, Scognamiglio G, Califano D, Arenare L, Schettino C, Pisano C, Cecere S C, Di Napoli M, Passarelli A, Perrone F, Pignata S, Scala S
细胞生物学
发表日期：2025
文献求助 收藏

Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials

主观症状报告不足及其预后价值：12项癌症临床试验的汇总分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.102941
Arenare, L; Di Liello, R; De Placido, P; Gridelli, C; Morabito, A; Pignata, S; Nuzzo, F; Avallone, A; Maiello, E; Gargiulo, P; Schettino, C; Gravina, A; Gallo, C; Chiodini, P; Di Maio, M; Perrone, F; Piccirillo, M C
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Corrigendum to "Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials": [ESMO Open 9 (2024) 102941]

对“主观症状报告不足及其预后价值：12 项癌症临床试验的汇总分析”的更正：[ESMO Open 9 (2024) 102941]

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103693
Arenare, L; Di Liello, R; De Placido, P; Gridelli, C; Morabito, A; Pignata, S; Nuzzo, F; Avallone, A; Maiello, E; Gargiulo, P; Schettino, C; Gravina, A; Gallo, C; Chiodini, P; Di Maio, M; Perrone, F; Piccirillo, M C
SMO
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏